ERBB2 and breast carcinoma: In contrast, the percentage of tumors having sTILs-TIM-3+ was similar among the different mammary carcinoma subtypes (above 94.1%), with the exception of the HER-2+ mammary carcinomas, in which only 77.8% of the tumors showed sTILs-TIM-3+ (Table 4).